Developer docs
API playgroundTry for free, no card

Search company profiles

Immunocore

Full company profile

uuid00005xm

Namestring
Immunocore
Legal namestring
Immunocore Holdings plc
Websiteurl
immunocore.com
Company typeenum
Public
Founded yearint
2008
Descriptiontext

Immunocore Holdings plc (NASDAQ: IMCR) is a UK-headquartered, commercial-stage biotechnology company founded in 2008 that pioneered the development of T cell receptor (TCR) bispecific immunotherapies through its proprietary ImmTAX platform. The company's core technology generates soluble TCR molecules engineered to recognize intracellular disease antigens with ultra-high affinity, fused to anti-CD3 immune-effector functions that redirect and activate T cells to destroy target cells. ImmTAX encompasses three modality families: ImmTAC for oncology, ImmTAV for infectious diseases, and gamma delta TCR technology for non-HLA restricted therapies developed with Gadeta. The platform has produced five clinical-stage programs.

The company's sole approved and commercialized product is KIMMTRAK (tebentafusp-tebn), a bispecific TCR targeting gp100 in melanocytes that received FDA approval in January 2022 as the first TCR therapeutic and first bispecific T cell engager approved for a solid tumor. KIMMTRAK is indicated for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma — a rare and aggressive eye cancer with no prior approved therapy — and has demonstrated statistically significant overall survival benefit (hazard ratio 0.51) with five-year survival of 16% versus 8% in the control arm. KIMMTRAK has subsequently received approval from the European Commission, UK MHRA, Australian TGA, Health Canada, and NICE.

Immunocore generates revenue primarily through KIMMTRAK product sales, with FY2025 net sales of $400M (29% YoY growth) and a 96.5% gross margin. Distribution occurs through specialty pharmacy networks and academic medical centers in the US and EU, supplemented by the Medison Pharma partnership covering Canada, Central Eastern Europe, and Israel. The KIMMTRAKConnect patient support program provides nurse case managers, financial assistance, and care coordination. Secondary revenue includes collaboration income from the Genentech/Roche co-development and co-promotion agreement for IMC-C103C (MAGE-A4) and Gates Foundation funding for HIV/HBV programs. The company maintains a cash position of $864.2M and a market valuation of approximately $1.6B.

Short descriptiontext

Immunocore is a UK-based commercial-stage biotechnology company that develops T cell receptor bispecific immunotherapies using its proprietary ImmTAX platform, commercializing KIMMTRAK (tebentafusp) as the first FDA-approved TCR therapeutic for HLA-A*02:01-positive metastatic uveal melanoma. The company serves rare disease oncology patients globally and has pipeline programs in solid tumors and infectious diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersAbingdon, United Kingdom
HQ citystring
Abingdon
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
TCR bispecific immunotherapies, ImmTAC platform therapeutics, oncology biologics, bispecific T cell engagers, cancer immunotherapy
Industry2 codes
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceuticals
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1KIMMTRAK Product Sales
TypeOne Time License
Description

Immunocore generates revenue primarily through sales of KIMMTRAK (tebentafusp-tebn), its FDA-approved treatment for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. The company commercializes the product directly in the US and EU markets and through distribution partners in other regions. Revenue is generated through product sales to specialty pharmacies and healthcare providers.

stocktitan.net
2Collaboration Revenue
TypeLicensing Royalties
Description

The company receives collaboration revenue from partnerships such as the co-development and co-promotion agreement with Genentech for IMC-C103C, where Immunocore shares program costs and profits equally. Additionally, the company receives funding from the Bill and Melinda Gates Foundation for HIV and hepatitis B programs.

immunocore.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain
Pricing details1 tier
1KIMMTRAK is provided as a prescription medication through specialty pharmacy channels with patient support services
ModelOtherBilling cadenceOther
Notes

Pricing not publicly disclosed; company provides financial assistance through KIMMTRAKConnect program

immunocore.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1KIMMTRAK (tebentafusp)
Description

The company's flagship approved product - a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function for treating metastatic uveal melanoma

immunocore.com
+3 more records
Core offering1 text field

Immunocore develops and commercializes T cell receptor (TCR) bispecific immunotherapies using its proprietary ImmTAX platform. Its flagship approved product KIMMTRAK (tebentafusp-tebn) is the world's first approved TCR therapeutic, indicated for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. The pipeline extends the ImmTAC and ImmTAV platforms to additional solid tumors and infectious diseases including HIV and hepatitis B.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • Overall survival hazard ratio of 0.51 (p<0.0001) in metastatic uveal melanoma Phase 3 trial
+5 more records
Product and service8 records
1KIMMTRAK (tebentafusp-tebn)
CategoryOncology Biologic / TCR Therapeutic
Description

FDA-approved TCR bispecific biologic for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma; first TCR therapeutic and first bispecific T cell engager approved for a solid tumor; sold to oncology specialty pharmacies and academic medical centers.

2KIMMTRAK (tebentafusp) - EU Marketing Authorization
CategoryOncology Biologic / TCR Therapeutic
Description

European Commission-approved version of KIMMTRAK for the same metastatic uveal melanoma indication, distributed through regional commercialization partners across EU markets.

3KIMMTRAK (tebentafusp) - UK, Australia, Canada Approval
CategoryOncology Biologic / TCR Therapeutic
Description

KIMMTRAK approved by UK MHRA, Australian TGA, and Health Canada for treatment of unresectable or metastatic uveal melanoma; sold through regional distribution and commercialization partners.

4IMC-C103C (MAGE-A4 ImmTAC)
CategoryClinical-stage Oncology Biologic
Description

Investigational ImmTAC bispecific T cell engager targeting MAGE-A4 for treatment of solid tumors including ovarian cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, gastric cancer, and synovial sarcoma; in clinical development under partnership with Genentech.

5IMC-M113V (HIV ImmTAV)
CategoryClinical-stage Infectious Disease Biologic
Description

Investigational ImmTAV bispecific therapy targeting the HIV Gag antigen presented on HLA-A*02-infected cells, being developed as a potential functional cure for HIV infection.

6IMC-I109V (Hepatitis B ImmTAV)
CategoryClinical-stage Infectious Disease Biologic
Description

Investigational ImmTAV bispecific therapy targeting a conserved hepatitis B virus envelope antigen, in development as a potential functional cure for chronic hepatitis B infection.

7Brenetafusp (PRAME-targeting ImmTAC)
CategoryClinical-stage Oncology Biologic
Description

Investigational PRAME-targeting ImmTAC bispecific therapy for heavily pretreated advanced melanoma; clinical-stage candidate with updated Phase 1/2 data reported at ASCO 2026.

8Gamma delta TCR ImmTAC (Gadeta collaboration)
CategoryClinical-stage Oncology Biologic
Description

Investigational non-HLA-restricted gamma delta TCR ImmTAC bispecific therapy for solid tumors including colorectal cancer, developed under a collaboration with Gadeta.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-02
Description

Immunocore and Gadeta entered into a collaboration agreement to develop the first gamma delta (γδ) TCR ImmTAC for solid tumors, including colorectal cancer. The collaboration combines Gadeta's gamma delta TCR identification expertise with Immunocore's TCR bispecific engineering and commercialization capabilities. Immunocore has an option for an exclusive license to further research, develop and commercialize ImmTAC candidates from the collaboration.

2Medison Pharma Ltd.
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-10-01
Description

Immunocore entered into an exclusive multi-regional agreement with Medison Pharma to help seek regulatory authorization and commercialize KIMMTRAK (tebentafusp) for the treatment of patients with metastatic uveal melanoma in Canada, twenty markets across Central Eastern Europe and Israel. Medison Pharma provides commercialization services including regulatory support and market access.

immunocore.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Immunocore and Genentech have a co-development and co-promotion collaboration for IMC-C103C, an ImmTAC molecule targeting MAGE-A4. Under the agreement, Immunocore shares program costs and profits equally with Genentech. The collaboration includes a Phase 1/2 dose escalation trial evaluating safety and preliminary clinical activity in solid tumors.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Bispecific antibody platform company (DuoBody) with multiple approved and clinical-stage T-cell engagers including epcoritamab (AbbVie partnership). Competes in the same bispecific T-cell redirection modality space as Immunocore's ImmTAC molecules.

TypeDirect peer
Description

Clinical-stage bispecific antibody developer (Margenza, enoblituzumab, vobramitamab duocarmazine) focused on solid tumors with DART and TRIDENT platforms enabling T-cell redirecting therapies similar to Immunocore's TCR bispecifics.

TypeDirect peer
Description

Developed T-cell engagers (HPN328 targeting DLL3, HPN217) for solid tumors using ProTriTAC and TriTAC platforms; acquired by Merck in 2024. Direct competitor in the T-cell engager space for solid tumors, though no longer independent.

TypeBroad incumbent
Description

Clinical-stage biotech with XmAb bispecific antibody platform developing T-cell engagers (e.g., vudalimab, plamotamab) and immune-modulating therapeutics. Competes in the bispecific T-cell redirection space with multiple oncology candidates.

TypeBroad incumbent
Description

Global oncology leader with Tagrisso, Imfinzi, Enhertu (with Daiichi Sankyo), and bispecific programs (datopotamab deruxtecan). Competes across solid tumor indications and represents a potential strategic partner or acquirer for pipeline assets.

TypeDirect peer
Description

Clinical-stage TCR therapy company focused on SPEAR T-cell receptor therapies for solid tumors, including MAGE-A4-targeted Tecelra (afami-cel). Closest direct peer with same TCR-targeting technology and shared MAGE-A4 program space (IMC-C103C).

TypeBroad incumbent
Description

Major bispecific antibody developer with VelociBi platform (linvoseltamab, odronextamab) competing in T-cell engaging therapeutics for solid tumors and hematologic malignancies; broader portfolio including Eylea, Dupixent, and Libtayo oncology.

8Bristol-Myers Squibb Company
TypeBroad incumbent
Description

Major oncology incumbent with Opdivo (PD-1), Yervoy (CTLA-4), and growing bispecific portfolio. Competes in IO/oncology space and represents both a partner candidate and a competitive threat across Immunocore's solid tumor pipeline.

TypeBroad incumbent
Description

Existing strategic partner on IMC-C103C (MAGE-A4) and broader oncology leader with multiple bispecifics and IO franchises. Both a commercial collaborator and competitive presence in the solid tumor T-cell engager space.

TypeEmerging player
Description

Clinical-stage allogeneic CAR-T cell therapy company targeting solid tumors and hematologic malignancies. Represents the cell therapy approach to TCR/CAR-based oncology therapeutics — adjacent modality to Immunocore's soluble TCR bispecifics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds9 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Immunocore

Biopharmaceuticalsimmunocore.com

Immunocore is a UK-based commercial-stage biotechnology company that develops T cell receptor bispecific immunotherapies using its proprietary ImmTAX platform, commercializing KIMMTRAK (tebentafusp) as the first FDA-approved TCR therapeutic for HLA-A*02:01-positive metastatic uveal melanoma. The company serves rare disease oncology patients globally and has pipeline programs in solid tumors and infectious diseases.

What Immunocore does

Immunocore Holdings plc (NASDAQ: IMCR) is a UK-headquartered, commercial-stage biotechnology company founded in 2008 that pioneered the development of T cell receptor (TCR) bispecific immunotherapies through its proprietary ImmTAX platform. The company's core technology generates soluble TCR molecules engineered to recognize intracellular disease antigens with ultra-high affinity, fused to anti-CD3 immune-effector functions that redirect and activate T cells to destroy target cells. ImmTAX encompasses three modality families: ImmTAC for oncology, ImmTAV for infectious diseases, and gamma delta TCR technology for non-HLA restricted therapies developed with Gadeta. The platform has produced five clinical-stage programs.

The company's sole approved and commercialized product is KIMMTRAK (tebentafusp-tebn), a bispecific TCR targeting gp100 in melanocytes that received FDA approval in January 2022 as the first TCR therapeutic and first bispecific T cell engager approved for a solid tumor. KIMMTRAK is indicated for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma — a rare and aggressive eye cancer with no prior approved therapy — and has demonstrated statistically significant overall survival benefit (hazard ratio 0.51) with five-year survival of 16% versus 8% in the control arm. KIMMTRAK has subsequently received approval from the European Commission, UK MHRA, Australian TGA, Health Canada, and NICE.

Immunocore generates revenue primarily through KIMMTRAK product sales, with FY2025 net sales of $400M (29% YoY growth) and a 96.5% gross margin. Distribution occurs through specialty pharmacy networks and academic medical centers in the US and EU, supplemented by the Medison Pharma partnership covering Canada, Central Eastern Europe, and Israel. The KIMMTRAKConnect patient support program provides nurse case managers, financial assistance, and care coordination. Secondary revenue includes collaboration income from the Genentech/Roche co-development and co-promotion agreement for IMC-C103C (MAGE-A4) and Gates Foundation funding for HIV/HBV programs. The company maintains a cash position of $864.2M and a market valuation of approximately $1.6B.

Immunocore firmographics

Firmographics
Name
Immunocore
Legal name
Immunocore Holdings plc
Website
https://immunocore.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Immunocore is a UK-based commercial-stage biotechnology company that develops T cell receptor bispecific immunotherapies using its proprietary ImmTAX platform, commercializing KIMMTRAK (tebentafusp) as the first FDA-approved TCR therapeutic for HLA-A*02:01-positive metastatic uveal melanoma. The company serves rare disease oncology patients globally and has pipeline programs in solid tumors and infectious diseases.
Ownership category
akta.pro rank

Immunocore industry classification

Industry
Product category
Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAABAC
CAR-T & TCR-T Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • TCR bispecific immunotherapies
  • ImmTAC platform therapeutics
  • Oncology biologics
  • Bispecific T cell engagers
  • Cancer immunotherapy

Where Immunocore is headquartered

Location

Headquarters

HQ city
Abingdon
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Immunocore business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. KIMMTRAK Product Sales: Immunocore generates revenue primarily through sales of KIMMTRAK (tebentafusp-tebn), its FDA-approved treatment for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. The company commercializes the product directly in the US and EU markets and through distribution partners in other regions. Revenue is generated through product sales to specialty pharmacies and healthcare providers.
  2. Collaboration Revenue: The company receives collaboration revenue from partnerships such as the co-development and co-promotion agreement with Genentech for IMC-C103C, where Immunocore shares program costs and profits equally. Additionally, the company receives funding from the Bill and Melinda Gates Foundation for HIV and hepatitis B programs.

Pricing tiers

ModelBillingPrice
OtherOtherKIMMTRAK is provided as a prescription medication through specialty pharmacy channels with patient support services

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Immunocore product offering

Product offering

Core offering

Immunocore develops and commercializes T cell receptor (TCR) bispecific immunotherapies using its proprietary ImmTAX platform. Its flagship approved product KIMMTRAK (tebentafusp-tebn) is the world's first approved TCR therapeutic, indicated for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. The pipeline extends the ImmTAC and ImmTAV platforms to additional solid tumors and infectious diseases including HIV and hepatitis B.

Differentiator

Problem solved

Functional benefit

Brands

  • KIMMTRAK (tebentafusp): The company's flagship approved product - a novel bispecific protein comprised of a soluble T cell receptor fused to an anti-CD3 immune-effector function for treating metastatic uveal melanoma
  • ImmTAX
  • ImmTAC
  • ImmTAV

Products and services

  • KIMMTRAK (tebentafusp-tebn) FDA-approved TCR bispecific biologic for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma; first TCR therapeutic and first bispecific T cell engager approved for a solid tumor; sold to oncology specialty pharmacies and academic medical centers.
  • KIMMTRAK (tebentafusp) - EU Marketing Authorization European Commission-approved version of KIMMTRAK for the same metastatic uveal melanoma indication, distributed through regional commercialization partners across EU markets.
  • KIMMTRAK (tebentafusp) - UK, Australia, Canada Approval KIMMTRAK approved by UK MHRA, Australian TGA, and Health Canada for treatment of unresectable or metastatic uveal melanoma; sold through regional distribution and commercialization partners.
  • IMC-C103C (MAGE-A4 ImmTAC) Investigational ImmTAC bispecific T cell engager targeting MAGE-A4 for treatment of solid tumors including ovarian cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, gastric cancer, and synovial sarcoma; in clinical development under partnership with Genentech.
  • IMC-M113V (HIV ImmTAV) Investigational ImmTAV bispecific therapy targeting the HIV Gag antigen presented on HLA-A*02-infected cells, being developed as a potential functional cure for HIV infection.
  • IMC-I109V (Hepatitis B ImmTAV) Investigational ImmTAV bispecific therapy targeting a conserved hepatitis B virus envelope antigen, in development as a potential functional cure for chronic hepatitis B infection.
  • Brenetafusp (PRAME-targeting ImmTAC) Investigational PRAME-targeting ImmTAC bispecific therapy for heavily pretreated advanced melanoma; clinical-stage candidate with updated Phase 1/2 data reported at ASCO 2026.
  • Gamma delta TCR ImmTAC (Gadeta collaboration) Investigational non-HLA-restricted gamma delta TCR ImmTAC bispecific therapy for solid tumors including colorectal cancer, developed under a collaboration with Gadeta.

Quantifiable outcome

  • Overall survival hazard ratio of 0.51 (p<0.0001) in metastatic uveal melanoma Phase 3 trial
  • +5 more outcomes

Companies that use Immunocore

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Immunocore technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Immunocore partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • GadetacoreStrategic or Co-development Partner · 2 December 2022Immunocore and Gadeta entered into a collaboration agreement to develop the first gamma delta (γδ) TCR ImmTAC for solid tumors, including colorectal cancer. The collaboration combines Gadeta's gamma delta TCR identification expertise with Immunocore's TCR bispecific engineering and commercialization capabilities. Immunocore has an option for an exclusive license to further research, develop and commercialize ImmTAC candidates from the collaboration.
  • Medison Pharma Ltd.coreChannel Partner/ Reseller/ Distributor · 1 October 2021Immunocore entered into an exclusive multi-regional agreement with Medison Pharma to help seek regulatory authorization and commercialize KIMMTRAK (tebentafusp) for the treatment of patients with metastatic uveal melanoma in Canada, twenty markets across Central Eastern Europe and Israel. Medison Pharma provides commercialization services including regulatory support and market access.
  • Genentech (Roche Group)coreStrategic or Co-development PartnerImmunocore and Genentech have a co-development and co-promotion collaboration for IMC-C103C, an ImmTAC molecule targeting MAGE-A4. Under the agreement, Immunocore shares program costs and profits equally with Genentech. The collaboration includes a Phase 1/2 dose escalation trial evaluating safety and preliminary clinical activity in solid tumors.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Immunocore competitors and assessment

Company assessment

Broad incumbents

  • Genmab A/S: Bispecific antibody platform company (DuoBody) with multiple approved and clinical-stage T-cell engagers including epcoritamab (AbbVie partnership). Competes in the same bispecific T-cell redirection modality space as Immunocore's ImmTAC molecules.
  • Xencor, Inc. Clinical-stage biotech with XmAb bispecific antibody platform developing T-cell engagers (e.g., vudalimab, plamotamab) and immune-modulating therapeutics. Competes in the bispecific T-cell redirection space with multiple oncology candidates.
  • AstraZeneca plc: Global oncology leader with Tagrisso, Imfinzi, Enhertu (with Daiichi Sankyo), and bispecific programs (datopotamab deruxtecan). Competes across solid tumor indications and represents a potential strategic partner or acquirer for pipeline assets.
  • Regeneron Pharmaceuticals, Inc. Major bispecific antibody developer with VelociBi platform (linvoseltamab, odronextamab) competing in T-cell engaging therapeutics for solid tumors and hematologic malignancies; broader portfolio including Eylea, Dupixent, and Libtayo oncology.
  • Bristol-Myers Squibb Company: Major oncology incumbent with Opdivo (PD-1), Yervoy (CTLA-4), and growing bispecific portfolio. Competes in IO/oncology space and represents both a partner candidate and a competitive threat across Immunocore's solid tumor pipeline.
  • Genentech (Roche Holding AG): Existing strategic partner on IMC-C103C (MAGE-A4) and broader oncology leader with multiple bispecifics and IO franchises. Both a commercial collaborator and competitive presence in the solid tumor T-cell engager space.

Direct peers

  • MacroGenics, Inc. Clinical-stage bispecific antibody developer (Margenza, enoblituzumab, vobramitamab duocarmazine) focused on solid tumors with DART and TRIDENT platforms enabling T-cell redirecting therapies similar to Immunocore's TCR bispecifics.
  • Harpoon Therapeutics (Merck): Developed T-cell engagers (HPN328 targeting DLL3, HPN217) for solid tumors using ProTriTAC and TriTAC platforms; acquired by Merck in 2024. Direct competitor in the T-cell engager space for solid tumors, though no longer independent.
  • Adaptimmune Therapeutics plc: Clinical-stage TCR therapy company focused on SPEAR T-cell receptor therapies for solid tumors, including MAGE-A4-targeted Tecelra (afami-cel). Closest direct peer with same TCR-targeting technology and shared MAGE-A4 program space (IMC-C103C).

Emerging players

  • Allogene Therapeutics, Inc. Clinical-stage allogeneic CAR-T cell therapy company targeting solid tumors and hematologic malignancies. Represents the cell therapy approach to TCR/CAR-based oncology therapeutics — adjacent modality to Immunocore's soluble TCR bispecifics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Immunocore social profiles

Digital presence

Immunocore financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Immunocore leadership team

Management profile

Number of profiles

Profiles7 records

Immunocore funding detail

Funding detail

Funding overview

Funding rounds9 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Immunocore M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Immunocore

What does Immunocore do?

Immunocore develops and commercializes T cell receptor (TCR) bispecific immunotherapies using its proprietary ImmTAX platform. Its flagship approved product KIMMTRAK (tebentafusp-tebn) is the world's first approved TCR therapeutic, indicated for HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. The pipeline extends the ImmTAC and ImmTAV platforms to additional solid tumors and infectious diseases including HIV and hepatitis B.

Is Immunocore a public or private company?

Immunocore is a public company. It is classified as public and is currently operating.

When was Immunocore founded?

Immunocore was founded in 2008. It employs 501 to 1,000 people.

Where is Immunocore based?

Immunocore is headquartered in Abingdon, United Kingdom, in the Europe region.

How does Immunocore make money?

Two revenue lines are on record. KIMMTRAK Product Sales are the primary driver. The others are collaboration Revenue.

Who are Immunocore's main competitors?

Broad incumbents on record are Genmab A/S, Xencor, Inc., AstraZeneca plc, Regeneron Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Genentech (Roche Holding AG). Direct peers are MacroGenics, Inc., Harpoon Therapeutics (Merck) and Adaptimmune Therapeutics plc. Allogene Therapeutics, Inc. is listed as an emerging player.

Does Immunocore have an API?

No public API is recorded for Immunocore.

What industry is Immunocore in?

Immunocore's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Investing.comImmunocore Holdings stock hits 52-week low at $27.40Immunocore Holdings stock hit a 52-week low of $27.40, down 21% over the past year. Baird reiterated an Outperform rating with a $84 price target after Phase 1/2 data showed Kimmtrak plus brenetafusp had greater durability in uveal melanoma. The company maintains financial flexibility with a current ratio of 4.62.Seeking AlphaImmunocore Holdings plc (IMCR) Presents at UBS Global Biopharma Conference 2026 TranscriptImmunocore CFO Travis Coy discussed KIMMTRAK's commercial progress at a UBS conference call, noting 70%+ penetration across markets. He said growth is moderating as the product becomes standard of care, with remaining growth drivers in community settings.Investing.comImmunocore at UBS Global Biopharma Conference 2026: KIMMTRAK drives growthImmunocore's CFO Travis Coy said KIMMTRAK has reached over 70% global penetration and is standard of care, with real-world therapy duration at about 14 months. The company reported $429 million revenue and over $900 million in cash, and highlighted KIMMTRAK plus brenetafusp data showing higher response rates and survival. TEBE-AM data is expected in Q2 2027.TradingViewMorgan Stanley maintains Immunocore Holdings at Equal-Weight, lowers price target to $42 from $43Morgan Stanley maintained Immunocore Holdings at Equal-Weight and lowered its price target to $42 from $43. The target implies a 37.8% upside from the Nov 12 close of $30.48.American Banking and Market NewsHC Wainwright Has Lowered Expectations for Immunocore (NASDAQ:IMCR) Stock PriceHC Wainwright cut Immunocore's price target to $80 from $100, keeping a Buy rating. The brokerage estimates Q1 2027 EPS at $0.17 and FY2027 EPS at $1.34. Immunocore shares opened at $31.65 on Tuesday.Business & FinancialImmunocore To Present At Upcoming Investor ConferencesImmunocore will present at the UBS Global Biopharma Conference on November 17, 2026, and Jefferies London conference on November 18, 2026. The company's KIMMTRAK therapy is approved for uveal melanoma in 39 countries. Presentations will be webcast live with a replay available.Simply Wall StIs Immunocore Holdings (IMCR) Undervalued On Third Quarter Earnings?Immunocore Holdings reported third-quarter and nine-month results, with shares rising 9.12% in one day to $30.99. Analysts estimate a fair value of $62.73, implying the stock is undervalued. The valuation hinges on successful Phase III melanoma trials and early autoimmune/HIV studies.The future of tradingImmunocore Publishes Presentation on Phase 1 Brenetafusp Study in Metastatic Uveal MelanomaImmunocore presented Phase 1 data on brenetafusp alone or with tebentafusp in metastatic uveal melanoma. The first-line combination cohort of 17 patients showed a 29% response rate, median progression-free survival of 8.1 months, and 70% two-year overall survival. The findings support further evaluation in the DUET-UVEAL Phase 2/3 study.Endpoints NewsImmunocore's T cell engager combo shows early potential in uveal melanomaImmunocore reported early test results for two bispecific T cell engagers combined in a solid tumor, showing estimated 70% of certain uveal melanoma patients responded. The company said the combo showed early potential in uveal melanoma.TradingViewImmunocore Holdings plc (IMCR) Reports 70% Two-Year Survival in 17-Patient CohortImmunocore reported 70% two-year overall survival in 17 evaluable first-line patients receiving brenetafusp plus tebentafusp, with median overall survival not reached. The company plans a randomized Phase 2/3 trial, and the survival signal is based on a small, non-randomized cohort.